Today

Agents

Chat

Arena

Discover

More

App

Cytokinetics CEO Robert I. Blum disposes of $526,800 in common shares - CYTK News | Rallies

Cytokinetics CEO Robert I. Blum disposes of $526,800 in common shares

CYTK•2026-08-31

CEO exercises options and sells shares

Cytokinetics President and CEO Robert I. Blum exercised stock options for 7,500 shares on Aug. 31, 2026 at $10.6.
Blum sold 7,500 shares the same day at $70.24.
Directly held common stock fell to 377,820 shares.
Directly held non-qualified stock options declined to 164,245.

Related News

Kyntra Bio says FibroGen Europe unit settles bankruptcy obligations for about $0.1 million

KYNB•2026-08-31

abrdn Australia Equity Fund NAV at $10.45 as of Aug. 27, 2026

IAF•2026-08-31

Brazil, US agree to hold new meetings to discuss tariffs as talks resume

Sources

S

Cytokinetics CEO Robert I. Blum disposes of $526,800 in common shares

Sec

•

2026-08-31

Primis Financial director Allen R. Jones Jr. resigns, exits Enterprise Risk Committee

FRST•2026-08-31

iSpecimen Appoints Shahin Behrozyan CEO, Katharyn Field To Leave Role

ISPC•2026-08-31